The stem cell sector is fueled by innovation and rapid change. To keep you up-to-date, we recently released new coverage of the industry. Check it out and let us know what you think! [Read more…]
Why Perinatal Stem Cells Are Gaining Momentum
Recently back from the Perinatal Stem Cell Society Conference in Aspen, CO, I am excited to share new coverage of the stem cell market with you. At this event, experts from around the world shared cutting-edge research about perinatal tissues over the course of three days (March 2-4, 2016).
We also have interviews with stem cell executives released below, including an interview with Dr. Jon Rowley, Founder and CEO of RoosterBio, and Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics. Enjoy this exclusive new content!
Did You See This Week’s Top Stem Cell News?
We’ve released new content on stem cell and cord blood markets that we are excited to share with you. Enjoy!
Q&A Interview with Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics
Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, 3D technology platform to develop cell therapies for a broad range of diseases. Pluristem Therapeutics specializes in placental-derived “PLX” cells, which are now being explored for applications that include critical limb ischemia (CLI), acute radiation syndrome (ARS), incomplete bone marrow engraftment, and more. [Read more…]
NIH’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome
Pluristem Therapeutics marks its first entry into the defense sector with today’s breaking news. NIAID, a part of the U.S. National Institutes of Health (NIH), will initiate studies in large animals to evaluate dosing for Pluristem’s PLX-R18 as a medical countermeasure in the treatment of the hematologic components of Acute Radiation Syndrome (ARS).
To learn more, read the full press issued by Pluristem, included below with permission from Janet Vasquez, Managing Director/Founder of JVPRVY. [Read more…]
We Interviewed Key Stem Cell Industry Leaders (Here’s What We Learned)
In groundbreaking news released January 2016, the Tisch MS Research Center of New York (MSRCNY) announced it is pursuing a Phase II clinical trial exploring spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (MSC-NPs) for the treatment of multiple sclerosis (MS).
Importantly, the Phase I trial was the first time in history that a treatment demonstrated reversal of established disability in MS patients. Therefore, we are excited to release an exclusive interview with Dr. Saud Sadiq, Chief Research Scientist for Tisch MSRCNY. [Read more…]
- « Previous Page
- Next Page »